Related Experiment Video

Updated: Dec 19, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.1K

Efficacy and Safety of Bushenjiangya-Optimized Granule for Left Ventricular Diastolic Dysfunction in Hypertensive

Qun Gao1, Xiao-Yun Cui2, Fei Dong3

  • 1Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100070, China.

Evidence-Based Complementary and Alternative Medicine : Ecam
|June 9, 2020
PubMed

Insights

Bushenjiangya-optimized (BSJYO) granule effectively treats left ventricular diastolic dysfunction (LVDD) in hypertensive patients. This therapy, combined with Western medicine, improved cardiac function and TCM symptoms safely over eight weeks.

Area of Science:

  • Cardiology
  • Integrative Medicine
  • Pharmacology

Background:

  • Hypertensive patients often develop left ventricular diastolic dysfunction (LVDD).
  • Traditional Chinese Medicine (TCM) offers potential therapeutic avenues for managing LVDD in hypertension.
  • Bushenjiangya-optimized (BSJYO) granule is a TCM formulation investigated for its effects on cardiovascular health.

Purpose of the Study:

  • To assess the efficacy and safety of BSJYO granule in treating LVDD among patients with hypertension (HTN).
  • To evaluate the impact of BSJYO granule on echocardiographic parameters, TCM syndromes, and blood pressure control.
  • To monitor adverse events and major adverse cardiovascular events (MACEs) in the study population.

Main Methods:

  • A randomized controlled trial involving 120 hypertensive patients with LVDD.
  • Participants were assigned to receive either BSJYO granule or a placebo, alongside standard Western medicine (WM).
  • Treatment duration was eight weeks, with assessments including echocardiography, TCM symptom scores, 24-hour ambulatory blood pressure, and laboratory tests. A 6-month follow-up for MACEs was conducted.

Main Results:

  • BSJYO granule significantly reduced E/Ea, an indicator of filling pressure and LVDD severity (P < 0.01).
  • The BSJYO granule group showed significant improvements in TCM symptom scores, with a total effective response rate of 71.70% (P < 0.01).
  • No significant differences were observed between groups regarding liver/kidney function, adverse events, or MACEs.

Conclusions:

  • BSJYO granule, when used as an adjunct to basal Western medicine, demonstrates efficacy in treating hypertensive patients with LVDD.
  • The treatment is safe, with no increased risk of adverse events or MACEs compared to placebo.
  • BSJYO granule represents a viable therapeutic option for managing LVDD in the context of hypertension.
Abstract

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.9K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

576

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
796
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
664
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
358
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
463
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
719
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
149